集中带量采购政策在有效降低药品价格、规范市场秩序的同时,也重塑了市场格局,对产业创新动力的结构产生了深远影响。在此背景下,创新药领域出现的“发展式转让”现象,既是我国医药产业链分工深化、资产流动国际化的体现,也在一定程度上反映了当前阶段本土企业独立进行全球研发与市场竞争的实力与信心尚有不足。为引导产业跨越这一阶段性瓶颈,护航本土创新力量成长并最终形成国际竞争力,系统研究该模式的不足与优化路径显得尤为必要。为此,本文基于权威数据与理论框架,在解析其现状与特征的基础上,致力于探讨如何从以下四个关键维度协同发力:第一,构建更可持续的资金支持体系;第二,完善激励长期创新的市场回报机制;第三,培育能承载全链条研发的产业生态;第四,加强引导产业升级的政策协同。 本研究旨在通过上述举措,为我国创新药产业从“可及”到“可控”、从“跟随”到“引领”的跨越式发展,提供坚实的系统性支持。
Abstract
While effectively reducing drug prices and standardizing market order, the centralized volume-based procurement policy has also reshaped the market landscape, exerting a profound impact on the structure of industrial innovation dynamics. Against this backdrop, the emergence of the "developmental out-licensing" phenomenon in the innovative drug sector reflects both the deepening division of labor within China's pharmaceutical industry chain and the internationalization of asset flows. It also, to some extent, indicates a current gap in the capability and confidence of domestic enterprises to independently engage in global R&D and market competition. To guide the industry through this developmental bottleneck, safeguard the growth of domestic innovative capacity, and ultimately foster international competitiveness, it is particularly necessary to systematically study the shortcomings and optimization pathways of this model. Therefore, based on authoritative data and theoretical frameworks, and after analyzing its current status and characteristics, this paper aims to explore how to synergize efforts from the following four key dimensions: first, constructing a more sustainable financial support system; second, improving market return mechanisms that incentivize long-term innovation; third, cultivating an industrial ecosystem capable of supporting full-chain R&D; and fourth, strengthening policy coordination to guide industrial upgrading. This research seeks to provide solid systemic support through the aforementioned measures for the leapfrog development of China's innovative drug industry from "accessibility" to "controllability", and from "following" to "leading".
关键词
集中带量采购 /
创新药 /
发展式转让 /
资产转让 /
产业治理 /
政策协同
Key words
centralized volume-based procurement /
innovative drugs /
developmental out-licensing /
asset out-licensing /
industrial governance /
policy coordination
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 滕莉莉,苏杭,陈煜之.集中带量采购政策对医药公司创新的影响研究——基于文本分析法的实证分析[J]. 价格理论与实践,2023(05):192-195.
[2] 吴迪,刘克军.集中带量采购政策背景下高值医用耗材治理改革的现状、困境及对策[J]. 中国卫生经济,2025,44(10):22-25.
[3] 刘振鹏,苏启林,郭娜娜.“靶向引领”如何影响园区产业创新?——以苏州工业园区生物医药产业为例[J]. 管理世界,2024,40(11):119-138.
[4] 蔡显军,卞宇轩,陈怡锋.药品集采与企业创新投入[J]. 科学决策,2023(12):102-118.
[5] 邓伟,吴俣煊.集中采购政策对医药企业研发效率的影响——来自我国A股上市公司的实证检验[J]. 工业技术经济,2024,43(02):50-59.
[6] 程文闻,刘小辉,张丝雨,等.国家药品集中带量采购政策对药企创新的影响研究[J]. 中国药事,2023,37(10):1101-1109.
[7] 周晨婷,申俊龙,陈小进.药品市场自由定价背景下政府有效监管机制探讨[J]. 中国卫生事业管理,2016,33(06):429-432.
[8] 刘跃华,刘昭,张萌.国际创新药基于疗效的价值定价机制案例研究[J]. 中国卫生经济,2020,39(06):61-64.
[9] 郑秉文. 我国医保支付方式改革:现状、挑战与趋势[J]. 人民论坛,2025(05):44-50.
[10] 艾丹丹,陈辰,吴婷婷,等.价值医疗背景下创新药品的定价和支付模式综述[J]. 中国卫生经济,2020,39(03):77-79.
[11] 郭志刚,洪冬喆,刘伊,等.我国基本药物集中采购量价挂钩实施影响因素分析[J]. 中国卫生政策研究,2015,8(12):1-6.
基金
山东省自然科学基金面上项目“社会互动和网络信息对家庭商业保险参与的影响研究”(ZR2022MG073); 山东省青少年教育科学研究院高等教育研究项目“医疗保险专业基于‘四个导向、五个维度’产教协同育人机制研究”(24HER041); 山东省青少年教育科学研究院高等教育研究项目“项目式学习在推动专业教育与思政教育协同育人中的模式设计与应用研究”(25HER109)